Focusing on individuals who had been treated with semaglutide 2.4 mg for 1 year introduced a potential selection bias, as these individuals were more likely to have experienced benefits and may have demonstrated higher adherence to the medication
[DOI] [PubMed] [Google Scholar] Sugiyama E., Hara A., Uemura K
It is important to note that tirzepatide is currently approved for use only in patients with T2DM and, therefore, its utility in non-diabetic MASLD/MASH individuals remains to be investigated
2 Methods 2.1 Data source Data on Individual Case Safety Reports (ICSRs) of suspected adverse drug reactions (ADRs) associated with semaglutide were retrieved from the EV database (EudraVigilance, 2025)
However, consult your doctor before receiving CARNISURE 1GM INJECTION
Association between Serum Uric Acid and Pre-hypertension and Hypertension among Chinese Adults